Combination of a cyclic hexapeptide with antifungal drugs for treatment of fungal pathogens

• US 6,875,740 B1
• Filed: 05/24/2000
• Issued: 04/05/2005
• Est. Priority Date: 05/31/1999
• Status: Expired due to Fees

• Current Assignee: Astellas Pharma Incorporated
• Original Assignee: Fujisawa Pharmaceutical Co., Ltd. (Astellas Pharma Incorporated)
• Inventors: Matsumoto, Satoru, Ikeda, Fumiaki, Otomo, Kazumi, Wakai, Yoshimi
• Primary Examiner(s): Weber, Jon
• Assistant Examiner(s): Mohamed, Abdel A.
• Application Number:
  US09/926,679
• Time in Patent Office: 1,777 Days
• Field of Search: 514/9, 514/8, 514/11, 514/23, 514/43, 514/49, 514/383, 530/317, 435/68.1, 435/231
• US Class Current: 514/3.6
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/70 Carbohydrates; Sugars; Derivatives thereof sorbitol A61K31/047
• CPC Class Codes: A61K 31/7048 having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin , digitoxin or digoxin
• CPC Class Codes: A61K 38/12 Cyclic peptides , e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C A61K38/043 - A61K38/046 take precedence
• CPC Class Codes: A61P 31/10 Antimycotics

Abstract

There is described antifungal combination use of known antifungal agents such as the azoles or polyenes in combination with a lipopeptide compound antifungal agent. More particularly, the invention relates to antifungal combination use of azols such as fluconazole voriconazole, itraconazole, ketoconazole, miconazole, ER 30346 and SCH 56592; polyenes such as amphotericin B, nystatin, liposomal and lipid forms thereof such as Abelcet, AmBisome and Amphocil; purine or pyrimidine nucleotide inhibitors such as flucytosine; or polyoxins such as nikkomycins, in particular nikkomycin Z or nikkomycin X; other chitin inhibitors; elongation factor inhibitors such as sordarin and analogs thereof; mannan inhibitors such as predamycin, bactericidal/permeability-inducing (BPI) protein products such as XMP.97 or XMP.127; or complex carbohydrate antifungal agents such as CAN-296; with a lipopeptide compound (I) as described herein.

Claims

1. A method for the treatment or inhibition of an infectious disease caused by Aspergillus fumigatus, which comprises;

administering an effective amount of a lipopeptide compound [I] of the following formula;

wherein R¹ is an acyl group, R² is hydrogen or hydroxy and R³ is hydrogen or hydroxy, or a pharmaceutically acceptable salt thereof, in combination with Amphotericin B, Itraconazole, Nikkomycin X or Flucytosine.

2. The method of claim 1, wherein the lipopeptide compound [I] is

or a salt thereof.

3. A pharmaceutical composition for the therapeutic treatment of an infectious disease caused by Aspergillus fumigatus, which comprises:

an effective amount of the lipopeptide compound [I] in claim 1 in combination with Amphotericin B, Itraconazole, Nikkomycin X or Flucytosine and optionally pharmaceutically acceptable carriers or excipients.

4. The method of claim 1, wherein the infectious disease is aspergillosis.

5. The method of claim 1, wherein the pharmaceutically acceptable salt of the lipopeptide compound [I] is formed from an inorganic base.

6. The method of claim 1, wherein the pharmaceutically acceptable salt of the lipopeptide compound [I] is formed from an organic base.

7. The method of claim 1, wherein said acyl group is aliphatic acyl, aromatic acyl, arylaliphatic acyl or heterocyclicaliphatic acyl.

8. The method of claim 7, wherein said aliphatic acyl is alkanoyl selected from the group consisting of formyl, acetyl, propanoyl, butanoyl, 2-methylpropanoyl, pentanoyl, 2,2-dimethylpropanoyl, hexanoyl, heptanoyl, octanoyl, nonanoyl, decanoyl, undecanoyl, dodecanoyl, tridecanoyl, tetradecanoyl, pentadecanoyl, hexadecanoyl, heptadecanoyl, octadecanoyl, nonadecanoyl and icosanoyl;

alkoxycarbonyl selected from the group consisting of methoxycarbonyl, ethoxycarbonyl t-butoxycarbonyl, t-pentyloxycarbonyl and heptyloxycarbonyl;

alkylsulfonyl selected from the group consisting of methylsulfonyl and ethylsulfonyl;

or alkoxysulfonyl selected from the group consisting of methoxysulfonyl and ethoxysulfonyl.

9. The method of claim 7, wherein said aromatic acyl is aroyl selected from the group consisting of benzoyl, toluoyl or naphthoyl;

substituted aroyl;

phenyl(C₁-C₆) alkanoyl selected from the group consisting of phenylacetyl, phenylpropanoyl, phenylbutanoyl, phenylisobutanoyl, phenylpentanoyl, phenylhexanoyl;

naphthyl(C₁-C₆) alkanoyl selected from the group consisting of naphthylacetyl, naphthylpropenoyl and naphthylbutanoyl;

phenyl (C₃-C₆) alkenoyl selected from the group consisting of phenylpropenoyl, phenylbutenoyl, phenylmethacryloyl, phenylpentanoyl and phenylhexenoyl;

naphthyl (C₃-C₆) alkenoyl selected from the group consisting of naphthylpropenoyl and naphthylbutenoyl;

phenyl (C₁-C₆) alkoxycarbonyl;

fluorenyl (C₁-C₆) alkoxycarbonyl;

aryloxycarbonyl selected from the group consisting of phenoxycarbonyl and naphthyloxycarbonyl;

aryloxy(lower)alkanoyl selected from the group consisting of phenoxyacetyl and phenoxypropionyl;

arylcarbamoyl;

arylthiocarbamoyl;

arylglyoxyloyl selected from the group consisting of phenylglyoxyloyl and naphthylglyoxyloyl;

or

arylsulfonyl selected from the group consisting of phenylsulfonyl and p-tolylsulfonyl.

10. The method of claim 7, wherein said heterocyclicaliphatic acyl is heterocyclic(lower)alkanoyl selected from the group consisting of heterocyclicacetyl, heterocyclicpropanoyl, heterocyclicbutenoyl heterocyclicpentanoyl and heterocyclichexanoyl;

heterocyclic(lower)alkenoyl selected from the group consisting of heterocyclicpropanoyl, heterocyclicbutenoyl, heterocyclicpentenoyl and heterocyclichexenoyl or heterocyclicglyoxyloyl.

11. The method of claim 7, wherein said acyl group is aroyl substituted by at least one heterocyclic group substituted by alkoxyaryl, at least one heterocyclic group substituted by lower alkoxy(lower)alkoxyaryl, at least one heterocyclic group substituted by lower alkoxy(higher)alkoxyaryl, at least one heterocylic group substituted by cyclo(lower)alkyloxyaryl, at least one heterocyclic group substituted by heterocyclicaryl, at least one heterocyclic group substituted by cyclo(lower)alkylcyclo(lower)alkyl, at least one heterocyclic group substituted by aryl substituted by lower oxy(lower)alkoxyaryl or at least one heterocyclic group substituted by aryl having a cyclo(lower)alkylheterocyclic group.

12. The method of claim 7, wherein said acyl group of R¹ is benzoyl substituted by pentyloxyphenylisoxazolyl, benzoyl substituted by pentyloxphenylimidazolthiadiazolyl, benzoyl substituted by methoxyhexyloxyphenylthiadiazolyl, benzoyl substituted by methoxyoctyloxyphenylthiadiazolyl, benzoyl substituted by methoxyheptyloxyphenylthiadiazolyl benzoyl substituted by cyclohexylophenylimidazothiadiazolyl, benzoyl substituted by dimethylmorpholinophenyllimidazothiadiazolyl, benzoyl substituted by methoxyheptyloxyphenylpiperazinyl, benzoyl substituted by methoxyoctyloxyphenylpiperazinyl benzoyl substituted by cyclohexylcyclohexylpiperazinyl, benzoyl substituted by methoxyethoxyphenylphenylthiadiazolyl, benzoyl substituted by methoxybutoxyphenylphenylthiazolyl benzoyl substituted by ethoxypropoxyphenylphenylthiadiazolyl, benzoyl substituted by cyclohexylpiperazinylphenylimidazothiadiazolyl or benzoyl substituted bycyclohexylpiperazinylphenylimidazothiadiazolyl.